Table 1

Effects of 10 μM CCh, 1 μM atropine alone, or co-application of CCh and atropine as indicated on the maximal amplitude of the field potentials, the maximal amplitude of EPSP (EPSPmax), the I50and slope factor of the EPSP input–output curve
Ctl (n = 7) CCh (n = 7) CCh + atro (n = 7)
Field max (mV) −0.53 ± 0.17 −0.16 ± 0.05 (*) −0.61 ± 0.15 (+)
EPSP max (mV) 18.8 ± 1.6 11.8 ± 1.6 (*) 19.1 ± 2.2 (+)
I50(V) 7.25 ± 1.15 8.36 ± 1.11 (*) 6.39 ± 1.13 (+)
Slope factor 1.44 ± 0.41 2.75 ± 0.2 (*) 1.26 ± 0.43 (+)
Ctl (n = 7) atro (n = 7) atro + CCh (n = 7)
Field max (mV) −0.63 ± 0.16 −0.73 ± 0.2 (*) −0.78 ± 0.21 (*)
EPSP max (mV) 21 ± 1.7 21 ± 1.8 21.8 ± 1.9
I50(V) 9.77 ± 0.78 9.5 ± 0.8 8.92 ± 0.62
Slope factor 2.12 ± 0.36 2.05 ± 0.29 2.26 ± 0.12

The order of two drugs given in the figures indicates the sequence of application (i.e. “CCh + atro” means atropine was added to a CCh containing ACSF and vice versa)

These experiments were performed in STRC

*: p < 0.05 vs. control, +: p < 0.05 vs. previous condition

Gigout et al.

Gigout et al. BMC Neuroscience 2012 13:42   doi:10.1186/1471-2202-13-42

Open Data